Carlyle Group Inc.
Institutional investor · Portfolio as of Q1 2023
Top Holdings30 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
QUIDELORTHO CORP | 12.5M | $1.1B | 33.1% | $100.03 | -11.95% | 4 qtrssince 2022-Q2 | Unchanged 0 |
ZOOMINFO TECHNOLOGIES INC | 36.7M | $905.9M | 27.0% | $50.72 | -51.85% | 12 qtrssince 2020-Q2 | Unchanged 0 |
MKS INC | 8.5M | $751.7M | 22.4% | $82.62 | +3.37% | 3 qtrssince 2022-Q3 | Unchanged 0 |
VITRU LTD | 6.2M | $142.2M | 4.2% | — | — | 11 qtrssince 2020-Q3 | Unchanged 0 |
GDS Holdings Ltd. Sponsored ADR Class A | 4.1M | $76M | 2.3% | $20.58 | -2.70% | 2 qtrssince 2022-Q4 | Increased 56 |
VAXCYTE INC | 1.9M | $72.1M | 2.2% | $36.27 | +60.10% | 1 qtr | New 78 |
GETTY IMAGES HOLDINGS INC | 11.9M | $60.6M | 1.8% | $5.55 | -8.11% | 2 qtrssince 2022-Q4 | Unchanged 0 |
VERONA PHARMA PLC | 2.5M | $49.3M | 1.5% | — | — | 1 qtr | New 68 |
HILLEVAX INC | 1.8M | $30.1M | 0.9% | — | — | 1 qtr | New 57 |
VERA THERAPEUTICS INC | 3M | $22.9M | 0.7% | $7.44 | 0.00% | 1 qtr | New 57 |
PHATHOM PHARMACEUTICALS INC | 2.9M | $20.9M | 0.6% | $6.80 | 0.00% | 1 qtr | New 56 |
Jasper Therapeutics, Inc. | 8.8M | $15.8M | 0.5% | — | — | — | — |
INVITATION HOMES INC | 477,500 | $14.9M | 0.4% | $27.70 | 0.00% | 1 qtr | New 48 |
| 2.1M | $12.2M | 0.4% | — | — | 1 qtr | New 47 | |
| 2.1M | $12.2M | 0.4% | — | — | 1 qtr | New 47 | |
LIFE STORAGE INC | 86,000 | $11.3M | 0.3% | — | — | 3 qtrssince 2022-Q3 | Unchanged 0 |
CUBESMART | 220,500 | $10.2M | 0.3% | $33.47 | +17.99% | 3 qtrssince 2022-Q3 | Unchanged 0 |
SEACOR MARINE HLDGS INC | 1.3M | $10M | 0.3% | $10.73 | -31.42% | 18 qtrssince 2018-Q4 | Increased 37 |
SPRUCE BIOSCIENCES INC | 2.9M | $6.4M | 0.2% | — | — | — | — |
SMART SH GLOBAL LTD | 4.8M | $5.3M | 0.2% | $1.12 | -4.46% | 4 qtrssince 2022-Q2 | Unchanged 0 |
Carlyle Group Inc. manages $3.4B across 30 positions as of Q1 2023. Top holdings: QDEL (33.1%), GTM (27.0%), MKSI (22.4%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 2.5/5.0.
Active quarter - 19 new positions, 2 exits, 2 increased. Top move: PCVX (NEW, conviction 78). Portfolio: $3.4B across 30 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
No active accumulation streaks detected for this filer.
Streaks require 2+ consecutive quarters of increased positions in the most recent period.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer